These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 879736)

  • 1. Synergistic action of erythromycin and cefamandole against Bacteroides fragilis subsp. fragilis.
    Griffith RS; Brier GL; Wolny JD
    Antimicrob Agents Chemother; 1977 May; 11(5):813-6. PubMed ID: 879736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity and synergism of cefuroxime on anaerobic bacteria.
    Thadepalli H; White DW; Bach VT
    Chemotherapy; 1981; 27(4):252-8. PubMed ID: 7249787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides.
    Fu KP; Neu HC
    J Infect Dis; 1978 May; 137 Suppl():S38-S50. PubMed ID: 349097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of beta-lactamase and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group.
    Malouin F; Lamothe F
    Can J Microbiol; 1987 Mar; 33(3):262-6. PubMed ID: 3105858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefamandole against Bacteroides fragilis.
    McAllister TA
    Scand J Infect Dis Suppl; 1980; suppl 25():32-6. PubMed ID: 6937949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the activity of first and second generation cephalosporins and their combinations with beta-lactamase inhibitors against Bacteroides fragilis.
    Martin MA; Liebana J; Castillo AM; Gutierrez J; Piédrola G
    Microbios; 1991; 67(272-273):195-202. PubMed ID: 1779879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis.
    Yotsuji A; Mitsuyama J; Hori R; Yasuda T; Saikawa I; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1848-53. PubMed ID: 3266730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of ciprofloxacin combined with flomoxef against Bacteroides fragilis, compared with that of ciprofloxacin combined with clindamycin.
    Kato K; Iwai S; Sato T; Harada T; Nakagawa Y; Iwanaga H; Ito Y; Takayama T
    J Infect Chemother; 2002 Jun; 8(2):190-3. PubMed ID: 12111577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteroides fragilis septicemia during cefamandole therapy.
    Righter J
    Can Med Assoc J; 1981 Sep; 125(5):422, 424. PubMed ID: 7284925
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.
    Hansen SL; Swomley P; Drusano G
    Antimicrob Agents Chemother; 1981 Feb; 19(2):335-6. PubMed ID: 6812492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis.
    Ralph ED; Amatnieks YE
    Antimicrob Agents Chemother; 1980 Mar; 17(3):379-82. PubMed ID: 6448574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group.
    Lamothe F; Auger F; Lacroix JM
    Antimicrob Agents Chemother; 1984 May; 25(5):662-5. PubMed ID: 6732233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to beta-lactam antibiotics and production of beta-lactamase in Bacteroides fragilis.
    Olsson B; Dornbusch K; Nord CE
    Med Microbiol Immunol; 1977 Oct; 163(3):183-94. PubMed ID: 243112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activity of seven antimicrobial agents against "Bacteroides fragilis" (author's transl)].
    Tytgat F
    Ann Microbiol (Paris); 1980; 131(1):39-44. PubMed ID: 6899739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antibiotics on the prevention of experimental Bacteroides fragilis endocarditis.
    Goldman PL; Durack DT; Petersdorf RG
    Antimicrob Agents Chemother; 1978 Nov; 14(5):755-60. PubMed ID: 727764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.
    Goldstein EJ; Citron DM; Cherubin CE
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1868-74. PubMed ID: 1952860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic.
    Darland G; Birnbaum J
    Antimicrob Agents Chemother; 1977 Apr; 11(4):725-34. PubMed ID: 856025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992.
    Dubreuil L; Breuil J; Dublanchet A; Sedallian A
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1094-9. PubMed ID: 1295764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    Chemioterapia; 1988 Aug; 7(4):264-6. PubMed ID: 2902937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.